Adverse events reported from recalled Systane Eye Drops by March 31, 2025?
Yes • 50%
No • 50%
FDA reports or Alcon Laboratories' official communications
Alcon Recalls Systane Lubricant Eye Drops Ultra PF, Lot 10101, Nationwide Due to Fungal Contamination
Dec 24, 2024, 05:31 PM
Alcon Laboratories, based in Fort Worth, Texas, has issued a voluntary recall of a single lot of Systane Lubricant Eye Drops Ultra PF due to potential fungal contamination. The affected product, sold in 25 single-use 'on-the-go' vials, was distributed nationwide to retail and online outlets including Walgreens, CVS, and Target. The recalled lot, identified by lot number 10101 and an expiration date of September 2025, was recalled after a consumer reported finding foreign material in a sealed vial, which was later confirmed to be fungal. The FDA warns that fungal contamination in eye products can lead to serious eye infections, potentially causing partial vision loss, blindness, or in rare cases, life-threatening conditions for immunocompromised individuals. No adverse events related to this recall have been reported to date. Consumers are advised to stop using the recalled eye drops immediately and return them to the place of purchase for a replacement or refund.
View original story
Decreased trust in Alcon • 25%
No significant change • 25%
Increased demand for safer packaging • 25%
Switch to alternative brands • 25%
Supply chain contamination • 25%
Manufacturing defect • 25%
Other cause • 25%
No specific cause identified • 25%
Other regions • 25%
North America • 25%
Europe • 25%
Asia • 25%
Increase by more than 10% • 25%
Other outcome • 25%
No significant change (+/- 10%) • 25%
Decrease by more than 10% • 25%
Mandatory product reformulation • 25%
Temporary production halt • 25%
No further action • 25%
Fine imposed • 25%
Alcon loses market share • 25%
Alcon gains market share • 25%
No significant change • 25%
Other outcome • 25%
Increased quality checks • 25%
Product reformulation • 25%
Discontinue product • 25%
No significant changes • 25%
Major compliance issues • 25%
Recall expanded • 25%
Minor compliance issues • 25%
No issues found • 25%